AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8929195 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine posture at sea level (SL)
Number of subjects: 18
Study 8929195 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture at sea level (SL)
Number of subjects: 18
Study 8929195 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined at altitude (ALT)
Number of subjects: 18
Study 8929195 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined at sea level (SL)
Number of subjects: 18
Study 1486186 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily in the morning
Number of subjects: 226
Study 1486186 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily at night
Number of subjects: 226
Study 6489418 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 registered pharmaceutical specialities
Number of subjects: 50
Study 6489418 — intervention group
Group type: COMPARATOR
Intervention: Generic equivalents
Number of subjects: 50
Study 30625145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative adversity score (each additional adversity)
Number of subjects: 1726
Study 29193527 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention for diabetes foot ulcer care
Number of subjects: 0
Study 29193527 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention in home-based care
Number of subjects: 0
Study 29193527 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 0
Study 27459498 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry graft tympanoplasty
Number of subjects: 100
Study 27459498 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet graft tympanoplasty
Number of subjects: 100
Study 25201587 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioguided seed localization (RSL)
Number of subjects: 73
Study 25201587 — intervention group
Group type: COMPARATOR
Intervention: Wire localization (WL)
Number of subjects: 73
Study 21900224 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Limiting Membrane (ILM) peeling
Number of subjects: 141
Study 21900224 — intervention group
Group type: COMPARATOR
Intervention: No peeling
Number of subjects: 141
Study 20536946 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of IGT
Number of subjects: 79
Study 20536946 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics of children who improved IGT
Number of subjects: 79
Study 20536946 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up characteristics of children who improved IGT
Number of subjects: 79
Study 20536946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubertal stage
Number of subjects: 79
Study 20536946 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors for normalization of IGT
Number of subjects: 79
Study 20536946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk factors and HOMA
Number of subjects: 79
Study 17663104 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine obstetric treatment with catgut embedding at Zusanli (ST 36) and Shangjuxu (ST 37)
Number of subjects: 300
Study 17663104 — intervention group
Group type: COMPARATOR
Intervention: Routine obstetric treatment
Number of subjects: 300
Study 16091264 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming of the position (subliminal and supraliminal)
Number of subjects: 0
Study 16091264 — intervention group
Group type: COMPARATOR
Intervention: No priming of the position
Number of subjects: 0
Study 12017421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 75-microg
Number of subjects: 538
Study 12017421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 150-microg
Number of subjects: 538
Study 12017421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (all doses)
Number of subjects: 538
Study 12017421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study 9890379 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Ondansetron (4 mg)
Number of subjects: 40
Study 9890379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7675936 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 IU AVP
Number of subjects: 12
Study 7675936 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms ANH
Number of subjects: 12
Study 7675936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1646490 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low molecular weight heparin (CY 216)
Number of subjects: 166
Study 1646490 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous unfractionated heparin
Number of subjects: 166
Study 6752926 — intervention group
Group type: EXPERIMENTAL
Intervention: Antrafenine (up to 1200 mg daily)
Number of subjects: 0
Study 6752926 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (up to 4 g daily)
Number of subjects: 0
Study 6752926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31365565 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 hours of mentored clinical practice
Number of subjects: 441
Study 31365565 — intervention group
Group type: COMPARATOR
Intervention: Usual training (control)
Number of subjects: 441
Study 31365565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (150 hours of mentored clinical practice)
Number of subjects: 441
Study 29130845 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive red-cell transfusion strategy (transfuse if hemoglobin <7.5 g/dL)
Number of subjects: 5243
Study 29130845 — intervention group
Group type: COMPARATOR
Intervention: Liberal red-cell transfusion strategy (transfuse if hemoglobin <9.5 g/dL in operating room or ICU, <8.5 g/dL in non-ICU ward)
Number of subjects: 5243
Study 29130845 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive red-cell transfusion strategy
Number of subjects: 5243
Study 29130845 — intervention group
Group type: COMPARATOR
Intervention: Liberal red-cell transfusion strategy
Number of subjects: 5243
Study 26559533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) with methylprednisolone
Number of subjects: 56
Study 26559533 — intervention group
Group type: COMPARATOR
Intervention: Placebo with methylprednisolone
Number of subjects: 56
Study 23975474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (PC) using the Dáder method
Number of subjects: 94
Study 23975474 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 94
Study 23975474 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of patients with therapeutic failure and non-adherence at the beginning of the trial (N = 50)
Number of subjects: 94
Study 23027071 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid minimally invasive oesophagectomy (HMIO)
Number of subjects: 0
Study 23027071 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (control)
Number of subjects: 0
Study 19535242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (2 years)
Number of subjects: 564
Study 19535242 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 564
Study 17513805 — intervention group
Group type: EXPERIMENTAL
Intervention: Six cycles of epirubicin 75 mg/m2 and docetaxel 75 mg/m2 on day 1 and granulocyte colony‐stimulating factor on days 3 through 10 (ED+G), every 21 days
Number of subjects: 288
Study 17513805 — intervention group
Group type: COMPARATOR
Intervention: Three cycles of epirubicin 75 mg/m2 and docetaxel 75 mg/m2 on day 1 and granulocyte colony‐stimulating factor on days 3 through 10 (ED+G), every 21 days
Number of subjects: 288
Study 17513805 — intervention group
Group type: EXPERIMENTAL
Intervention: Six cycles of ED+G
Number of subjects: 288
Study 17513805 — intervention group
Group type: COMPARATOR
Intervention: Three cycles of ED+G
Number of subjects: 288
Study 15208047 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose formulation of Depo-Provera (104 mg/0.65 mL)
Number of subjects: 0
Study 15208047 — intervention group
Group type: COMPARATOR
Intervention: Original formulation of Depo-Provera (150 mg/mL)
Number of subjects: 0
Study 11782825 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-motor-threshold TENS
Number of subjects: 40
Study 11782825 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 11782825 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-motor-threshold TENS
Number of subjects: 40
Study 11782825 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception-threshold TENS
Number of subjects: 40
Study 11782825 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study 9830248 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 135
Study 9830248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 9830248 — intervention group
Group type: COMPARATOR
Intervention: No alcohol
Number of subjects: 135
Study 11271342 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 81
Study 11271342 — intervention group
Group type: COMPARATOR
Intervention: CyA/AzA
Number of subjects: 81
Study 2567049 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphasalazine
Number of subjects: 54
Study 2567049 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 54
Study 30894004 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Primary Care + Coaching (EPC + C)
Number of subjects: 360
Study 30894004 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Primary Care (EPC)
Number of subjects: 360
Study 28640168 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring in MST
Number of subjects: 20
Study 28640168 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring in ECT
Number of subjects: 20
Study 28640168 — intervention group
Group type: COMPARATOR
Intervention: no-BIS monitoring in MST
Number of subjects: 20
Study 28640168 — intervention group
Group type: COMPARATOR
Intervention: no-BIS monitoring in ECT
Number of subjects: 20
Study 28640168 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS condition
Number of subjects: 20
Study 28640168 — intervention group
Group type: COMPARATOR
Intervention: no-BIS condition
Number of subjects: 20
Study 26538423 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hemithoracic radiotherapy
Number of subjects: 151
Study 26538423 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 151
Study 26538423 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and extrapleural pneumonectomy
Number of subjects: 151
Study 26538423 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 151
Study 23744726 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide plus metformin
Number of subjects: 174
Study 23744726 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus metformin
Number of subjects: 174
Study 21295742 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones 120 mg/d
Number of subjects: 171
Study 21295742 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones 80 mg/d
Number of subjects: 171
Study 21295742 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (both doses)
Number of subjects: 171
Study 21295742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 19426751 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite face stimuli with horizontal and vertical misalignment
Number of subjects: 0
Study 19426751 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite face stimuli with stereo-depth separation
Number of subjects: 0
Study 19426751 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite face stimuli slanted through stereo-depth
Number of subjects: 0
Study 16991073 — intervention group
Group type: EXPERIMENTAL
Intervention: PFN
Number of subjects: 240
Study 16991073 — intervention group
Group type: COMPARATOR
Intervention: GLN
Number of subjects: 240
Study 15493037 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy per 10 fractions (n = 110)
Number of subjects: 214
Study 15493037 — intervention group
Group type: COMPARATOR
Intervention: 40 Gy per 20 fractions (n = 104)
Number of subjects: 214
Study 15278681 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cytokine measurements (IL-1beta, TNFalpha, IL-6)
Number of subjects: 118
Study 15278681 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum IL-6
Number of subjects: 118
Study 15278681 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cytokine concentrations
Number of subjects: 118
Study 10030393 — intervention group
Group type: EXPERIMENTAL
Intervention: E3/E3 genotype
Number of subjects: 142
Study 10030393 — intervention group
Group type: EXPERIMENTAL
Intervention: E3/E4 genotype
Number of subjects: 142
Study 10030393 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/3 genotype
Number of subjects: 142
Study 10030393 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE E4 allele presence
Number of subjects: 142
Study 10030393 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors (diet and lifestyle)
Number of subjects: 142
Study 7588455 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 111
Study 7588455 — intervention group
Group type: COMPARATOR
Intervention: Concomitant b.i.d. medications
Number of subjects: 111
Study 7588455 — intervention group
Group type: COMPARATOR
Intervention: Thrice-daily (t.i.d.) medications
Number of subjects: 111
Study 7588455 — intervention group
Group type: COMPARATOR
Intervention: Four times daily (q.i.d.) medications
Number of subjects: 111
Study 2351342 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (modified Program 1 plus isoradial chamber)
Number of subjects: 20
Study 458990 — intervention group
Group type: EXPERIMENTAL
Intervention: Emepronium bromide
Number of subjects: 15
Study 458990 — intervention group
Group type: COMPARATOR
Intervention: Flavoxate hydrochloride
Number of subjects: 15
Study 458990 — intervention group
Group type: COMPARATOR
Intervention: Imipramine hydrochloride
Number of subjects: 15
Study 31158260 — intervention group
Group type: EXPERIMENTAL
Intervention: Various randomization procedures
Number of subjects: 0
Study 31158260 — intervention group
Group type: EXPERIMENTAL
Intervention: Log-rank test
Number of subjects: 0
Study 31158260 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis
Number of subjects: 0
Study 27500463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex® treatment
Number of subjects: 30
Study 27500463 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 26471236 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E 200 mg
Number of subjects: 44
Study 26471236 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E 400 mg
Number of subjects: 44
Study 26471236 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E 600 mg
Number of subjects: 44
Study 26471236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 26158157 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (60 mg/d)
Number of subjects: 60
Study 26158157 — intervention group
Group type: COMPARATOR
Intervention: Control (without pyridoxine)
Number of subjects: 60
Study 23020850 — intervention group
Group type: EXPERIMENTAL
Intervention: Belly dance (16 weeks, twice a week)
Number of subjects: 80
Study 19053980 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 g/d prebiotic
Number of subjects: 44
Study 19053980 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g/d prebiotic
Number of subjects: 44
Study 19053980 — intervention group
Group type: COMPARATOR
Intervention: 7 g/d placebo
Number of subjects: 44
Study 17410063 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty/stenting (CAS)
Number of subjects: 0
Study 17410063 — intervention group
Group type: EXPERIMENTAL
Intervention: Endarterectomy
Number of subjects: 0
Study 17410063 — intervention group
Group type: COMPARATOR
Intervention: Randomised trials
Number of subjects: 0
Study 15068719 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemofiltration (CVVH) combined with conventional therapy
Number of subjects: 37
Study 15068719 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 37
Study 11879209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (5000 unit x kg(‐1))
Number of subjects: 30
Study 11879209 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy adult patients without hepatic cirrhosis)
Number of subjects: 30
Study 11879209 — intervention group
Group type: COMPARATOR
Intervention: Cirrhosis/saline
Number of subjects: 30
Study 9850013 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg transbuccal melatonin
Number of subjects: 12
Study 9850013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8272296 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep en bloc closure
Number of subjects: 23
Study 8272296 — intervention group
Group type: COMPARATOR
Intervention: Superficial skin closure
Number of subjects: 23
Study 2531117 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose spectinomycin (TRO: 2 g intramuscularly)
Number of subjects: 400
Study 2531117 — intervention group
Group type: COMPARATOR
Intervention: Aqueous procaine penicillin G (APPG: 4.8 x 10(6) units) plus 1 g of probenecid
Number of subjects: 400
Study 2531117 — intervention group
Group type: COMPARATOR
Intervention: Aqueous procaine penicillin G (APPG)
Number of subjects: 400
Study 2531117 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose spectinomycin (TRO)
Number of subjects: 400
Study 30554932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided ankle block
Number of subjects: 50
Study 30554932 — intervention group
Group type: COMPARATOR
Intervention: Metatarsal block
Number of subjects: 50
Study 31409342 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=217)
Number of subjects: 633
Study 31409342 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=218)
Number of subjects: 633
Study 28034484 — intervention group
Group type: EXPERIMENTAL
Intervention: GEB application with McGRATH
Number of subjects: 16
Study 28034484 — intervention group
Group type: EXPERIMENTAL
Intervention: GEB application with AWS
Number of subjects: 16
Study 28034484 — intervention group
Group type: EXPERIMENTAL
Intervention: GEB application with McL
Number of subjects: 16
Study 28034484 — intervention group
Group type: COMPARATOR
Intervention: McGRATH without GEB
Number of subjects: 16
Study 28034484 — intervention group
Group type: COMPARATOR
Intervention: AWS without GEB
Number of subjects: 16
Study 28034484 — intervention group
Group type: COMPARATOR
Intervention: McL without GEB
Number of subjects: 16
Study 28034484 — intervention group
Group type: EXPERIMENTAL
Intervention: McGRATH with GEB
Number of subjects: 16
Study 28034484 — intervention group
Group type: EXPERIMENTAL
Intervention: AWS with GEB
Number of subjects: 16
Study 28034484 — intervention group
Group type: EXPERIMENTAL
Intervention: McL with GEB
Number of subjects: 16
Study 26480938 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 120
Study 26480938 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 120
Study 23391516 — intervention group
Group type: EXPERIMENTAL
Intervention: Training attention toward threat
Number of subjects: 34
Study 23391516 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 34
Study 21699484 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl 25 mg once daily
Number of subjects: 227
Study 21699484 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl 75 mg once daily
Number of subjects: 227
Study 21699484 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl 150 mg once daily
Number of subjects: 227
Study 21699484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 19130936 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 group sessions led by a community social worker and 6 home visits by community health workers
Number of subjects: 42
Study 19130936 — intervention group
Group type: COMPARATOR
Intervention: Mailed asthma education materials
Number of subjects: 42
Study 17346524 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 25
Study 17346524 — intervention group
Group type: COMPARATOR
Intervention: Abdominal myomectomy
Number of subjects: 25
Study 15380912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (3 x 125 ml, 2.38 MJ/day)
Number of subjects: 56
Study 15380912 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar amounts of a non-caloric fluid)
Number of subjects: 56
Study 11808987 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy for 3 weeks
Number of subjects: 102
Study 9756115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy (total dose 1050 mg over seven consecutive dialysis sessions and supplemental monthly doses)
Number of subjects: 22
Study 9756115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron therapy
Number of subjects: 22
Study 7848600 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-2
Number of subjects: 469
Study 7848600 — intervention group
Group type: COMPARATOR
Intervention: HIV-1
Number of subjects: 469
Study 2899188 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high-carbohydrate diet (15% of calories from fat, increased complex carbohydrates)
Number of subjects: 21
Study 2899188 — intervention group
Group type: COMPARATOR
Intervention: Control group (general dietary advice)
Number of subjects: 21
Study 2899188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (low-fat diet)
Number of subjects: 21
Study 30654852 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural sleep intervention (two sessions covering sleep hygiene and standardized behavioral strategies)
Number of subjects: 244
Study 30654852 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural sleep intervention
Number of subjects: 244
Study 30664454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall TIPS modalities (EHR version, laminated paper version, bedside display version)
Number of subjects: 1209
Study 30664454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall TIPS modalities
Number of subjects: 1209